-
Guidelines Subcommittee. 1999 World
Health Organization-International Society of Hypertension Guidelines
for the Management of Hypertension. J Hypertens 1999; 17: 151-183.
-
De la Sierra A, Lluch MM, Coca A, et al.
Fluid, ionic and hormonal changes induced by high salt intake in
salt-sensitive and salt-resistant hypertensive patients.Clin Sci 1996;
91: 155-161.
-
Aguilera MT, De la Sierra A, Coca A, et
al. Effect of alcohol abstinence on blood pressure: assessment by
24-hour ambulatory blood pressure monitoring. Hypertension 1999; 33:
653-657.
-
Appel LJ, Moore TJ, Obarzanek E, et al.
A clinical trial of the effects of dietary patterns on blood pressure.
DASH Collaborative Research Group. N Engl J Med 1997; 336: 1117-1124.
-
Hansson L, Lindholm LH, Niskanen L, et
al. Effect of angiotensin-converting-enzyme inhibition compared with
conventional therapyon cardiovascular morbidity and mortality in
hypertension: the Captopril Prevention Project (CAPPP) randomised
trial. Lancet 1999; 353: 611-616.
-
Hansson L, Lindholm LH, Ekbom, et al.
Randomised trial of old and new antihypertensive drugs in elderly
patients: cardiovascular mortality and morbidity in the Swedish Trial
in Old Patients with Hypertension-2 study. Lancet 1999; 354:
1751-1756.
-
Hansson L, Hedner T, Lund-Johansen P, et
al. Randomised trial of effects of calcium antagonist compared with
diuretics and ß-blockers on cardiovascular morbidity and mortality in
hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000,
356:359-365.
-
Brown MJ, Palmer CR, Castaigne A, et al.
Morbidity and mortality in patients randomised to double-blind
treatment with long-acting calcium-channel blocker or diuretic in the
International Nifedipine GITS study: intervention as a goal in
hypertension treatment (INSIGHT). Lancet 2000; 356:366-372.
-
The ALLHAT Officers and Coordinators for
the ALLHAT Collaborative Research Group. Major cardiovascular events
in hypertensive patients randomized to doxazosin vs chlortalidone: The
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack
Trial (ALLHAT) JAMA 2000;283:1967-1975.
-
Pitt B, Zannad F, Remme WJ, et al. The
effect of spironolactone on morbidity and mortality in patients with
severe heart failure. Randomized Aldactone Evaluation Study
Investigators. N Engl J Med 1999; 341: 709-717.
-
Franse LV, Pahor M, Di Bari M, et al.
Hipokalemia associated with diuretic use and cardiovascular events in
the Systolic Hypertension in the Elderly Program. Hypertension 2000;
35: 1025-1030.
-
Wikstrand J, Warnold I, Olsson G, et al.
Primary prevention with metoprolol in patients with hypertension.
Mortality results from the MAPHY study. JAMA 1988; 259: 1976-1982.
-
Beta-blocker Heart Attack Trial
Investigators. A randomized trial of propranolol in patients with
acute myocardial infarction. I. Mortality results. JAMA 1982; 247:
1707-1714.
-
Packer M, Bristow MR, Cohn JN, et al.
The effect of carvedilol on morbidity and mortality in patients with
chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N
Engl J Med 1996; 334: 1349-1355.
-
CIBIS II Investigators and Committees.
The Cardiac Insuficiency Bisoprolol Study II (CIBIS-II): a randomised
trial. Lancet 1999; 353: 9-13.
-
MERIT-HF Investigators. Effect of
metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised
Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet
1999; 353: 2001-2007.
-
Gress TW, Nieto FJ, Shahar, et al. for
the Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342:
905-912.
-
UK Prospective Diabetes Study Group.
Efficacy of atenolol and captopril in reducing risk of macrovascular
and microvascular complications in type 2 diabetes: UKPDS 39. BMJ
1998; 317: 713-720.
-
Staessen JA, Fagard R, Thijs L, et al.
Randomised double-blind comparison of placebo and active treatment for
elder patients with isolated systolic hypertension. Lancet 1997; 350:
757-764.
-
Hansson L, Zanchetti A, Carruthers SG,
et al. Effects of intensive blood-pressure lowering and low-dose
aspirin in patients with hypertension: principal results of the
Hypertension Optimal Treatment (HOT) randomised trial. HOT Study
Group. Lancet 1998; 351: 1755-1762.
-
Pfeffer MA, Braunwald E, Moye LA, et al.
Effect of captopril on mortality and morbidity in patients with left
ventricular dysfunction after myocardial infarction. Results of the
survival and ventricular enlargement trial. The SAVE Investigators. N
Engl J Med 1992; 327: 669-677.
-
The Acute Infarction Ramipril Efficacy
(AIRE) Study Investigators. Effect of ramipril on mortality and
morbidity of survivors of acute myocardial infarction with clinical
evidence of heart failure. Lancet 1993; 342: 821-828.
-
The CONSENSUS Trial Study Group. Effects
of enalapril on mortality in severe congestive heart failure. Results
of the Cooperative North Scandinavian Enalapril Survival Study
(CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
-
The SOLVD Investigators. Effect of
enalapril on survival in patients with reduced left ventricular
ejection fractions and congestive heart failure. N Engl J Med 1991;
325: 293-302.
-
Lewis EJ, Hunsicker LG, Bain RP, Rohde
RD, for the Collaborative Study Group. The effect of
angiotensin-converting enzyme therapy on diabetic nephropathy. N Engl
J Med 1993; 329: 1456-1462.
-
Pitt B, Poole-Wilson PA, Segal R, et al.
Effect of losartan compared with captopril on mortality in patients
with symptomatic heart failure: randomised trial- the Losartan Heart
Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.
-
Cohn JN, Tognoni G. Effect of the
angiotensin receptor blocker valsartan on morbidity and mortality in
heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
Circulation 2000; 102: 2672 [Abstract].
-
Coca A, Gabriel R, De la Figuera M, López-Sendón
JL, Fernández R, Sagastagoitia JD, García JJ, Barajas R, on behalf
of the VITAE Investigators. The impact of different echocardiographic
diagnostic criteria on the prevalence of left ventricular hypertrophy
in essential hypertension: the VITAE study. J Hypertens 1999; 17:
1471-1480.
-
Verdecchia P, Schillaci G, Borgioni C,
et al. Prognostic significance of serial changes in left ventricular
mass in essential hypertension. Circulation 1998; 97: 48-54.
-
Schmieder RE, Martus P, Klingbeil A.
Reversal of left ventricular hypertrophy in essential hypertension. A
meta-analysis of randomized double-blind studies. JAMA 1996; 275:
1507-1513.
-
Estacio RO, Jeffers BW, Hiatt WR, et al.
The effect of nisoldipine as compared with enalapril on cardiovascular
outcomes in patients with non-insulin-dependent diabetes and
hypertension. N Engl J Med 19978; 338: 645-652.
-
Tatti P, Pahor M, Byington RP, et al.
Outcome results of the Fosinopril versus Amlodipine Cardiovascular
Events Randomized Trial (FACET) in patients with hypertension and
NIDDM. Diabetes Care 1998; 21: 597-603.
-
The Multicenter Diltiazem
Postinfarctaction Trial Research Group: The effect of diltiazem on
mortality and reinfarction after myocardial infarction. N Engl
J Med 1988; 319: 385-392.
-
The Danish Study Group on Verapamil in
Myocardial Infarction: Effect of verapamil on mortality and major
events after acute myocardial infarction (The Danish Verapamil
Infarction Trial-II-DAVIT-II). Am J Cardiol 1990; 66: 779-785.
-
The Heart Outcomes Prevention Evaluation
Study Investigators. Effects of an angiotensin-converting-enzyme
inhibitor, ramipril, on cardiovascular events in high-risk patients. N
Engl J Med 2000; 342: 145-153.
-
Packer M, Poole-Wilson PA, Armstrong PW,
et al. Comparative effects of low and high doses of the
angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and
mortality in chronic heart failure. Circulation 1999;100:2312-2318.
-
Pitt B, Segal R, Martinez FA, et al.
Randomised trial of losartan versus captopril in patients over 65 with
heart failure (Evaluation of Losartan in the Elderly Study, ELITE).
Lancet 1997; 349: 747-752.
-
Packer M, O´Connor CM, Ghali JK, et
al.. Effect of amlodipine on morbidity and mortality in severe chronic
heart failure. Prospective Randomized Amlodipine Survival Evaluation
Study Group. N Engl J Med 1996; 335: 1107-1114.
-
Heart Outcomes Prevention Evaluation
(HOPE) Study Investigators. Effects of ramipril on cardiovascular and
microvascular outcomes in people with diabetes mellitus: results of
the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-259.
-
UK Prospective Diabetes Study Group.
Tight blood pressure control and risk of macrovascular and
microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;
317: 703-712.
-
Curb JD, Pressel SL, Cutler JA, et al.
Effect of diuretic-based antihypertensive treatment on cardiovascular
disease risk in older diabetic patients with isolated systolic
hypertension. Systolic Hypertension in the Elderly Program Cooperative
Research Group. JAMA 1996; 276: 1886-1892.
-
Lindholm LH, Hansson L, Ekbom T, et al.
Comparison of antihypertensive treatments in preventing cardiovascular
events in elderly diabetic patients: results from the Swedish Trial in
Old Patients with Hypertension –2. J Hypertens 2000; 18: 1671-1675.
-
Wang JG, Staessen JA, Gong L, Liu L.
Chinese trial on isolated systolic hypertension in the elderly.
Systolic Hypertension in China (Syst-China) Collaborative Group. Arch
Intern Med 2000; 160: 211-220.
-
Sobrino J, Coca A. Manual de crisis
hipertensivas. Ediciones MRA, Barcelona 1999; 1-93.
-
Calhoun DA, Oparil S. Treatment of
hypertensive crisis. N Eng J Med 1990; 323: 1177-1183.
-
O'Mailia JJ, Sander GE, Giles TD.
Nifedipine-associated myocardial ischemia or infarction in the
treatment of hypertensive urgencies. Ann Intern Med 1987; 107:
185-186.
-
Documento de Consenso de las Sociedades
Catalanas de Hipertensión Arterial y de Neurología. Conducta ante la
elevación de la presión arterial en la fase aguda del Ictus.
Academia de Ciencias Médicas de Cataluña y Baleares. Barcelona,
Diciembre de 1999.
